TICKERNERD
Menu
PALIPALIHealthcare · Biotechnology

PALI Stock Forecast: Palisade Bio, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.45
−2.03% on the day

The 8 Wall Street analysts covering Palisade Bio, Inc. hold a median 12-month price target of $8 — +451.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$259.7M
Ticker Nerd rank
39 / 100
Median analyst target
$8.00
Analysts covering
8
Revenue$500K
Operating income−$11.7M
Net income−$10.6M
Free cash flow−$7.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.4%
1M
−34.1%
YTD
−38.3%
1Y
−27.5%
From 52W high
−48.2%
From 52W low
+7.4%
$1.35
$2.80
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PALI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Palisade Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
77
Size
64
Volatility
51
Quality
51
Value
48
Accruals
47
Revisions
41
Growth
29
Issuance
27

Momentum (77): The shares have been drifting up relative to others.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PALI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PALI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26PALIHigh $25.00Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $5.00Median $8.00High $25.00

The green dot is the last close — the median target sits +451.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Sept 2026HC Wainwright & Co.ReiteratesBuy$7.00
23 July 2026OppenheimerInitiatesOutperform$8.00
23 July 2026OppenheimerInitiatesOutperform—
9 Apr 2026Wolfe ResearchInitiatesOutperform—
9 Apr 2026Wolfe ResearchInitiatesOutperform$7.00
26 Mar 2026HC Wainwright & Co.InitiatesBuy—
25 Feb 2026StifelInitiatesBuy—
9 Jan 2026B. Riley SecuritiesInitiatesBuy—
30 Dec 2025Clear StreetInitiatesBuy—
29 Dec 2025Piper SandlerInitiatesOverweight—
13 May 2025Brookline CapitalMaintainsBuy—
20 Nov 2024Brookline CapitalInitiatesBuy—
13 Nov 2024Maxim GroupMaintainsBuy—
1 May 2024Maxim GroupReiteratesBuy—
16 Apr 2024Maxim GroupMaintainsBuy—
17 Nov 2023Maxim GroupUpgradeBuy—
16 May 2023Ladenburg ThalmannMaintainsBuy—
30 Mar 2023Maxim GroupUpgradeBuy—
19 Aug 2022Maxim GroupDowngradeHold—
2 Feb 2022Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PALI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PALI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Palisade Bio, Inc. returned −27.5% against +16.2% for the S&P 500, dividends included.

PALI vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26PALIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PALI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
5
Fundamentals

Palisade Bio, Inc. (PALI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.5×

Cheaper than 69% of US stocks

Price / sales
514.1×

Cheaper than 2% of US stocks

Price / book
2.1×

Cheaper than 42% of US stocks

EV / EBITDA
−3.8×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−2339.6%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−51.4%

Higher than 21% of US stocks

Return on assets
−33.0%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Palisade Bio, Inc. (PALI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Palisade Bio, Inc. has a market value of $259.7M and an enterprise value of $134.5M.

  • Revenue in the twelve months to 30 June 2026: $500K.

  • Net income over the same four quarters: −$31.9M, a −6388.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$18.2M.

  • Shares outstanding: 173.8M.

  • Trailing P/E: 2.5×; forward P/E: −5.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Palisade Bio, Inc. employs 14 people — $36K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

PALI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PALIPalisade Bio, Inc.$259.7M
39
LXEOLexeo Therapeutics, Inc.$252.1M
27
STROSutro Biopharma, Inc.$251.1M
74
UPBUpstream Bio, Inc.$249.2M
26
LCTXLineage Cell Therapeutics, Inc.$256.6M
58
FATEFate Therapeutics, Inc.$247.6M
96
ACIUAC Immune SA$259.5M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Palisade Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PALI news & analysis

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026

GlobeNewsWire · 28 Sept 2026positive

Palisade Bio announced it will present clinical and translational data for PALI-2108 in ulcerative colitis and Crohn's disease at UEG Week 2026. The oral presentation will highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn's disease.

Why it matters — The presentation signals progress for PALI-2108's development and could give PALI watchers new insight into the therapy's clinical and translational profile.

Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's

MarketBeat · 27 Sept 2026positive

Palisade Bio announced it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease, following the completion of its Phase I program.

Why it matters — This marks a significant clinical milestone for Palisade Bio as its lead candidate moves closer to potential market approval in two inflammatory bowel disease indications.

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

GlobeNewsWire · 23 Sept 2026positive

Palisade Bio announced that Health Canada has cleared its Clinical Trial Application for ASCENTRA-UC, its global Phase 2 study evaluating once-daily oral PALI-2108 in patients with moderately to severely active ulcerative colitis. The clearance supports site activation and enrollment, with primary efficacy results from approximately 204 patients expected in the second half of 2027.

Why it matters — This regulatory clearance expands the ASCENTRA-UC program into Canada, advancing enrollment and progress toward a key upcoming readout for PALI-2108.

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD

GlobeNewsWire · 22 Sept 2026positive

Palisade Bio announced that the FDA cleared its Investigational New Drug application for PALI-2108, allowing initiation of the Phase 2 ASCENTRA-CD trial in patients with moderate to severe Crohn's disease. The trial plans to enroll approximately 60 patients, with first dosing targeted for Q1 2027 and a primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028.

Why it matters — A PALI watcher would care because this FDA clearance and initiation of the Phase 2 Crohn's disease trial expands the company's development pipeline across inflammatory bowel disease beyond its existing fibrostenotic Crohn's program.

Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

GlobeNewsWire · 21 Sept 2026neutral

Palisade Bio announced that CEO JD Finley and Mitchell Jones, M.D. will present at the Stifel 2026 Virtual Immunology and Inflammation Forum, scheduled for September 23, 2026 at 1:00 PM ET, with a webcast available to access.

Why it matters — A Palisade Bio watcher would care because the presentation offers a public opportunity for the company's leaders to discuss its clinical-stage prodrug programs for inflammatory and fibrotic diseases.

FAQ

Frequently asked questions about PALI stock

What is the PALI stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Palisade Bio, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PALI stock a buy right now?

Of the 8 analysts covering Palisade Bio, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palisade Bio, Inc. 39 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PALI?

As at 8 Oct 2026, Palisade Bio, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (77 of 100).

Will PALI stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +451.7% from the last close, and Ticker Nerd's factor model ranks Palisade Bio, Inc. 39 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PALI stock forecast for 2030?

No analyst covering Palisade Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PALI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $25 over the next 12 months.

How has PALI stock performed over the past year?

Palisade Bio, Inc. returned -27.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Palisade Bio, Inc. do?

Palisade Bio Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory and fibrotic diseases.

What is the latest news on PALI?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026". Palisade Bio announced it will present clinical and translational data for PALI-2108 in ulcerative colitis and Crohn's disease at UEG Week 2026. The oral presentation will highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn's disease.

Company

About Palisade Bio, Inc.

Palisade Bio Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral phosphodiesterase-4 (PDE4) inhibitor prodrug designed for targeted activation in the ileum and colon, with an emphasis on localized treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The company’s current pipeline also includes additional gastrointestinal-focused programs aimed at protecting the intestinal barrier and addressing postoperative complications. Palisade Bio works with research and development partners to advance its drug candidates through clinical studies and product development, positioning the company within the specialty biopharmaceutical segment of the healthcare market.

CEO Mr. J. D. Finley · 14 employees · United States · https://www.palisadebio.com